Overview

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Status:
Completed

Trial end date:
2017-02-15

Target enrollment:

Participant gender:

Summary

This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).

Phase:

Phase 2

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborator:

GlaxoSmithKline